• Interim results of a Phase II international study (N = 25; 20 evaluable) for patients with BRAF V600E mutation-positive NSCLC
• Dabrafenib demonstrated ORR of 40%
• Safety profile of dabrafenib in NSCLC is consistent with previous studies in melanoma

This stunning data set adds significantly to the growing body of evidence revealing that targetable mutations found in one solid tumor may be associated with treatment benefit from novel agents developed for other cancer types. In this Phase II effort, the recently approved antimelanoma agent dabrafenib demonstrated indisputable objective responses in 8 patients with NSCLC and BRAF V600E mutations. Clearly more research will be done quickly on a variety of BRAF inhibitors, but it will be fascinating to observe whether the current body of evidence is enough to push investigators and general oncologists to consider and/or employ this strategy outside of a clinical trial. Equally relevant, on a macro level this study strengthens the belief of many that future treatment paradigms will be determined more by the presence of molecular targets than the organ of origin.